申联生物(688098) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 116,354,484.54, representing a decrease of 21.55% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 27,192,127.78, down 44.59% year-on-year[5]. - The basic earnings per share decreased to CNY 0.07, a decline of 41.67% compared to the previous year[6]. - The net profit attributable to shareholders decreased by 44.59% in the current reporting period due to the ongoing low performance of the pig breeding industry[11]. - The total revenue for the first three quarters decreased by 16.46% year-on-year, with a revenue drop of 21.55% in the third quarter[11]. - Net profit for the third quarter of 2023 was CNY 36,484,405.67, a decline of 49.6% from CNY 72,349,115.33 in the same quarter of 2022[22]. - The total comprehensive income attributable to the parent company for Q3 2023 was CNY 37,124,297.77, a decrease from CNY 72,362,110.69 in Q3 2022, reflecting a decline of approximately 48.7%[23]. - Basic and diluted earnings per share for Q3 2023 were both CNY 0.09, down from CNY 0.18 in Q3 2022, indicating a 50% decrease[23]. Research and Development - Research and development expenses amounted to CNY 13,927,155.79, a decrease of 41.47% year-on-year, accounting for 11.97% of revenue[6]. - Research and development expenses decreased by 41.47% in the current reporting period due to a reduction in capitalized R&D expenditures[11]. - Research and development expenses for the first three quarters of 2023 amounted to CNY 30,259,274.15, an increase of 14.1% compared to CNY 26,393,024.56 in 2022[21]. Cash Flow and Liquidity - The company reported a cash flow from operating activities of CNY -54,675,362.33 for the year-to-date[5]. - Cash inflow from operating activities for the first three quarters of 2023 was CNY 141,632,602.99, compared to CNY 147,079,311.43 in the same period of 2022, representing a decline of about 3.0%[26]. - The net cash flow from operating activities for the first three quarters of 2023 was -CNY 54,675,362.33, worsening from -CNY 41,221,111.53 in the previous year[26]. - The ending cash and cash equivalents balance for Q3 2023 was CNY 38,876,146.49, an increase from CNY 25,280,141.36 at the end of Q3 2022[27]. - The company's cash and cash equivalents decreased from 52,742,562.11 RMB at the end of 2022 to 39,005,070.45 RMB as of September 30, 2023[17]. - The company's cash and cash equivalents were CNY 631,999,472.35, down from CNY 705,503,694.52 in the previous year, indicating a decrease of 10.4%[20]. - The company reported a cash outflow of CNY 64,232,476.75 for employee compensation in the first three quarters of 2023, up from CNY 56,883,254.65 in the same period of 2022, indicating an increase of about 12.4%[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,611,375,470.59, reflecting a slight increase of 0.39% from the beginning of the year[6]. - The company's total assets as of the end of the third quarter of 2023 were CNY 1,611,375,470.59, slightly up from CNY 1,605,150,595.38 at the end of 2022[20]. - Total liabilities decreased to CNY 89,552,103.93 in the third quarter of 2023 from CNY 108,279,555.46 in the same quarter of 2022, a reduction of 17.3%[19]. - The company's total equity attributable to shareholders was CNY 1,502,459,258.76, an increase from CNY 1,496,871,039.92 in the previous year, representing a growth of 0.4%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,649[13]. - The largest shareholder, Yang Yufang, holds 21.93% of the shares, while the second-largest shareholder, UNITED BIOMEDICAL, INC., holds 10.52%[14]. Other Information - Non-operating income included government subsidies totaling CNY 268,958.78 for the current period[10]. - The company experienced a loss of CNY 341,413.60 from the disposal of non-current assets in the current period[10]. - The company is experiencing a decline in government procurement sales of foot-and-mouth disease vaccines, impacting overall revenue[11]. - The company has not disclosed any significant new strategies or market expansions in the current report[16].